Community-based sero-prevalence of chikungunya and yellow fever in the South Omo Valley of Southern Ethiopia.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Chikungunya Fever
/ blood
Chikungunya virus
/ immunology
Child
Cross-Sectional Studies
Ethiopia
/ epidemiology
Female
Humans
Male
Middle Aged
Residence Characteristics
Seroepidemiologic Studies
Yellow Fever
/ blood
Yellow fever virus
/ immunology
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
24
12
2019
accepted:
01
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
28
10
2020
Statut:
epublish
Résumé
Chikungunya (CHIK) and yellow fever (YF) are becoming major public health threats in East African countries including Ethiopia. In Ethiopia, there is no reliable information about the epidemiology of CHIK. This study aimed to assess a community-based sero-prevalence of CHIK and YF in the South Omo Valley, an endemic area for YF. Between February and June 2018, blood samples were collected from study participants and screened for IgG antibody against CHIK virus (CHIKV) and YF virus (YFV) infections using ELISA. Data were computerized using Epi Data Software v.3.1 and analyzed using SPSS. A total of 360 participants (51.7% males, age range from 6 to 80, mean age ± SD = 31.95 ± 14.05 years) participated in this study. The overall sero-prevalence of IgG antibody was 43.6% (157/360) against CHIKV, while it was 49.5% (155/313) against YFV. Out of 155 samples which were positive for IgG antibody to YFV, 93 (60.0%) were positive for IgG antibody to CHIKV. Out of 158 samples which were negative for IgG antibody to YFV, 64(40.5%) were positive for IgG antibody to CHIKV. There was a significant positive correlation between IgG antibodies to CHIKV and YFV (sr = 0.82; P<0.01). Residency in the Debub Ari district (AOR = 8.47; 95% CI: 1.50, 47.74) and travel history to sylvatic areas (AOR = 2.21; 95% CI: 1.02, 4.81) were significantly and positively associated with high sero-prevalence of IgG antibody to CHIKV and YFV, respectively. High sero-prevalence of IgG antibody to CHIKV shows the circulation of the virus in the present study area. A low sero-prevalence of IgG antibody to YFV in YF vaccine received individuals is highly concerning from a public health point of view as waning of immune response to YFV infection could result in a periodic outbreaks of YF in endemic areas.Nevertheless, the present study has not investigated for possible cross-reactivity of antibody to CHIKV with other alphaviruses like O'nyong-nyong virus and antibody to YFV with other flaviviruses like Dengue fever virus and this warrants further studies in the present study area.
Sections du résumé
BACKGROUND
Chikungunya (CHIK) and yellow fever (YF) are becoming major public health threats in East African countries including Ethiopia. In Ethiopia, there is no reliable information about the epidemiology of CHIK. This study aimed to assess a community-based sero-prevalence of CHIK and YF in the South Omo Valley, an endemic area for YF.
METHODS
Between February and June 2018, blood samples were collected from study participants and screened for IgG antibody against CHIK virus (CHIKV) and YF virus (YFV) infections using ELISA. Data were computerized using Epi Data Software v.3.1 and analyzed using SPSS.
RESULTS
A total of 360 participants (51.7% males, age range from 6 to 80, mean age ± SD = 31.95 ± 14.05 years) participated in this study. The overall sero-prevalence of IgG antibody was 43.6% (157/360) against CHIKV, while it was 49.5% (155/313) against YFV. Out of 155 samples which were positive for IgG antibody to YFV, 93 (60.0%) were positive for IgG antibody to CHIKV. Out of 158 samples which were negative for IgG antibody to YFV, 64(40.5%) were positive for IgG antibody to CHIKV. There was a significant positive correlation between IgG antibodies to CHIKV and YFV (sr = 0.82; P<0.01). Residency in the Debub Ari district (AOR = 8.47; 95% CI: 1.50, 47.74) and travel history to sylvatic areas (AOR = 2.21; 95% CI: 1.02, 4.81) were significantly and positively associated with high sero-prevalence of IgG antibody to CHIKV and YFV, respectively.
CONCLUSION
High sero-prevalence of IgG antibody to CHIKV shows the circulation of the virus in the present study area. A low sero-prevalence of IgG antibody to YFV in YF vaccine received individuals is highly concerning from a public health point of view as waning of immune response to YFV infection could result in a periodic outbreaks of YF in endemic areas.Nevertheless, the present study has not investigated for possible cross-reactivity of antibody to CHIKV with other alphaviruses like O'nyong-nyong virus and antibody to YFV with other flaviviruses like Dengue fever virus and this warrants further studies in the present study area.
Identifiants
pubmed: 32881913
doi: 10.1371/journal.pntd.0008549
pii: PNTD-D-19-02159
pmc: PMC7470273
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008549Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Bull World Health Organ. 1964;30:299-319
pubmed: 14163955
Am J Trop Med Hyg. 2011 Jul;85(1):158-61
pubmed: 21734142
Public Health. 2019 Jan;166:79-88
pubmed: 30468973
Am J Trop Med Hyg. 2002 May;66(5):533-41
pubmed: 12201587
BMC Public Health. 2018 Aug 14;18(1):1011
pubmed: 30107830
Parasit Vectors. 2014 Aug 20;7:382
pubmed: 25141888
Res Virol. 1995 Jan-Feb;146(1):69-73
pubmed: 7754238
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3335
pubmed: 25412076
Trans R Soc Trop Med Hyg. 2014 Oct;108(10):608-15
pubmed: 24947520
Trans R Soc Trop Med Hyg. 1971;65(2):152-68
pubmed: 4997499
BMC Infect Dis. 2017 May 15;17(1):343
pubmed: 28506254
Arch Virol. 1979;59(3):231-8
pubmed: 88212
BMC Public Health. 2019 May 28;19(1):650
pubmed: 31138178
Trop Med Int Health. 1999 Dec;4(12):867-71
pubmed: 10632996
PLoS Negl Trop Dis. 2018 Apr 9;12(4):e0006409
pubmed: 29630594
PeerJ. 2019 Feb 20;7:e6466
pubmed: 30809451
PLoS One. 2018 Oct 11;13(10):e0205058
pubmed: 30308064
Open Forum Infect Dis. 2019 Jan 03;6(3):ofz001
pubmed: 31660384
Microbes Infect. 2002 Nov;4(14):1459-68
pubmed: 12475636
PLoS Negl Trop Dis. 2017 Jan 20;11(1):e0005319
pubmed: 28107342
Emerg Infect Dis. 2013 Nov;19(11):1836-8
pubmed: 24210089
Clin Lab Med. 2010 Mar;30(1):237-60
pubmed: 20513550
Virol J. 2011 Jul 27;8:371
pubmed: 21794131
PLoS Negl Trop Dis. 2017 Dec 27;11(12):e0006163
pubmed: 29281644
Am J Trop Med Hyg. 2014 Jun;90(6):1003-13
pubmed: 24615140
Am J Trop Med Hyg. 2008 Feb;78(2):333-7
pubmed: 18256441
Viruses. 2020 Feb 10;12(2):
pubmed: 32050663
Am J Trop Med Hyg. 2017 Nov;97(5):1399-1404
pubmed: 29016323
PLoS Negl Trop Dis. 2018 May 31;12(5):e0006430
pubmed: 29852020
Pathog Glob Health. 2017 Sep;111(6):271-275
pubmed: 28829253
Rev Salud Publica (Bogota). 2008 Mar-May;10(2):299-307
pubmed: 19039426
Pathogens. 2019 Jul 27;8(3):
pubmed: 31357631
PLoS Med. 2014 May 06;11(5):e1001638
pubmed: 24800812
PLoS Negl Trop Dis. 2015 Jan 08;9(1):e3445
pubmed: 25568956
Jpn J Infect Dis. 2015;68(3):230-4
pubmed: 25672346
Clin Exp Vaccine Res. 2014 Jan;3(1):58-77
pubmed: 24427764
Trop Geogr Med. 1976 Dec;28(4):309-15
pubmed: 13526
Microbes Infect. 2002 Oct;4(12):1209-15
pubmed: 12467761
Trans R Soc Trop Med Hyg. 2008 Dec;102(12):1247-54
pubmed: 18502458
BMC Infect Dis. 2016 Apr 26;16:183
pubmed: 27112553
Emerg Infect Dis. 2016 Oct;22(10):1854-5
pubmed: 27536787
Rev Inst Med Trop Sao Paulo. 2017 Apr 03;59:e2
pubmed: 28380113
Am J Trop Med Hyg. 2010 Jun;82(6):1146-52
pubmed: 20519615